Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Endocrine Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

relacorilant 2pembrolizumab 2cabozantinib 2tariquidar 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Gefitinib 1Floxuridine 1Dexamethasone 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adrenal Cortex Neoplasms × tariquidar × Clear all
NCT00071058 2012-09-18

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled 10 charts

Adrenal Cortex Neoplasms, Endocrine Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡